Introduction
Novel agents, namely the immunomodulatory drugs Thalidomide and Lenalidomide, and the proteasome inhibitor Bortezomib, were tested in different clinical trials and led to good results in patients with multiple myeloma (MM). In particular, benefits with novel agents were also seen in relapsed/refractory multiple myeloma (rrMM) 1 .
Besides the approved regimens, new combinations containing novel drugs with/without conventional chemotherapies and/or steroids have been studied for the treatment of rrMM. To date, no comparative studies are available to help physicians choose the best treatment for rrMM patients.
Treatment choice for rrMM is based on prior therapy, remission duration and toxicity of treatment, patient's comorbidities and disease characteristics at relapse. Direct evidence and more precise guidelines are needed.
This review reports on the latest data and evidence about treatment of rrMM.
Is quality of response a critical end-point?
In newly diagnosed multiple myeloma (MM) patients, a complete response (CR) is a surrogate marker of long-term outcome. After the introduction of novel drugs, CR has become a more achievable aim, also for rrMM patients. However, the role of CR in these patients needs to be validated. Table 1 summarizes the studies addressing this issue. A retrospective study investigated the relationship between response rate and outcome in more than 300 patients with rrMM treated with thalidomide dexamethasone. In this study, the achievement of CR and very good partial response (VGPR) was associated with a significantly longer progression-free survival (PFS) and overall survival (OS) compared with partial response (PR) and stable disease (SD) 2 . In another retrospective analysis on rrMM patients treated with the combination of Doxil, Vincristine, lowdose dexamethasone and Thalidomide (DVd-T) found that patients achieving CR/VGPR had a significantly better PFS and OS compared with those achieving PR/SD 3 .
In the randomized phase III APEX trial, a post-hoc analysis including patients treated with bortezomib as single agent showed a relation between CR and both better treatment free interval (TFI) and better time to alternative therapy (TTAT), although time-to-progression (TTP) and OS were similar 4 . These results were consistent with those reported in a retrospective analysis on 70 patients treated with bortezomib dexamethasone 5 . Patients obtaining CR/VGPR had a considerably better TTP, TTAT, TFI compared with those achieving PR. In another study, the combination of bortezomib with doxorubicin and dexamethasone led to a significant higher eventfree survival (EFS) in patients obtaining CR/VGPR if compared with PR 6 . In a recent observational study, 769 patients were treated with bortezomib-based therapy. After at least 4 courses of therapy, CR rate was 12% and near CR (nCR) 16% 7 . These patients had a significantly improved survival compared with those who did not achieved CR and nCR. Another trial assessed the role of the 4-drug combination Thalidomide-Doxil-Dexamethasone-Bortezomib (ThaDD-V) 8 .
Patients who achieved CR had a significantly longer PFS compared with those achieving a lower response. In this study, patients attaining a stringent CR (sCR) had a better outcome than those achieving CR only. This demonstrates the importance of a deeper response also in rrMM.
A post-hoc analysis pooled data from two trials comparing patients treated with lenalidomide and high-dose dexamethasone [9] . In this analysis, patients achieving CR/VGPR had a significantly better TTP and OS compared with those achieving PR. This benefit was independent of when CR/VGPR was achieved and it was confirmed by a landmark analysis at 12-months. However, the two groups of patients were not well balanced. Patients who achieved CR/VGPR had a shorter disease history and received less prior treatments, particularly with thalidomide. No adjustment for these important factors was made in this study, and this is a major limitation.
These studies suggest that rrMM patients who achieve deeper response have a better outcome, at least in terms of PFS. These data should be considered with caution, since they derive from retrospective studies. Well-designed prospective studies are warranted to establish the relationship between response and outcome in rrMM.
Choosing treatment for patients with suboptimal response to induction regimen
Overall response rate (ORR/ at least PR) after first-line therapy with novel agents accounts for 57-100% 10-12 . MM patients considered "truly" refractory to induction therapy,i.e. those who fail to reach at least PR after three cycles of induction with novel agent-containing therapy, as defined in recent guidelines provided by an international panel of experts 13 , may need salvage treatment
In the non-transplant setting, the role of therapy aiming to improve depth of response should be investigated. No benefit with this approach was seen in elderly patients failing to reach at least PR, since these patients may have difficulties in prolonging treatment. Better quality of response was associated with improved long-term outcomes with VMP treatment, regardless of whether best response, in particular CR, was achieved early or late (even after 24 weeks of treatment strictly associated with the number of drugs used. As showed in Table 2 , the incidence of neutropenia, infections and DVT with regimens including 3 or 4 drugs were comparable with those reported with 2-drug combinations. However, thrombocytopenia and neuropathy are more common when 3-or 4-drug combinations including bortezomib are used. In order to improve outcome by reducing toxicity, some studies demonstrated that reducing bortezomib schedule from twice-to once-weekly administration significantly decreases bortezomib-induced peripheral neuropathy 28-30 . These more complex regimens are beneficial also in rrMM, provided that patients have not particular contraindications, such as neuropathy, and if they are able to tolerate potential toxicities associated with such combinations, for instance thrombocytopenia and neuropathy. Replacing thalidomide with lenalidomide and reducing bortezomib dose-intensity may improve outcome and decrease non-hematological toxicity.
How long should rrMM therapy last?
In Some studies investigated re-treatment with bortezomib after an adequate rest period. Patients enrolled in VISTA trial, who relapsed after VMP and were re-treated with bortezomib, had a CR rate similar to patients treated with lenalidomide-or thalidomide-based salvage therapy 30 .
Ongoing prospective study (RETREIVE study) demonstrated that re-treatment with bortezomib is feasible and safe but the benefits of this strategy needs to be confirmed 43 .
A recent sub-analysis pooled MM-09 and MM010 studies [9] . Patients achieving PR after induction with LD had 50% probability of obtaining CR/VGPR with further treatment and this response upgrade translated into a better outcome. However, in this study, 60% of patients tolerated and continued therapy after induction, and only 30% remained in the landmark analysis at 12 months.
Long-term treatment with LD is feasible and well-tolerated although severe hematologic toxicity, infections and thrombosis are a considerable drawback. Further investigation will define clinical and biological characteristics of patients who are more likely to benefit from long-term therapy. To date, no specific study has assessed which is the patient population that benefits more from this approach. In particular, the role of prolonged treatment remains controversial in elderly patients for whom long-term therapy may be detrimental. Therefore, a close evaluation of the risk/benefit ratio is warranted.
What is the impact of prior therapy?
Most young and elderly patients with newly diagnosed MM are currently treated with combinations containing at least one new drug. Identifying the best approach at relapse is difficult, especially considering that all patients have already been exposed to thalidomide, lenalidomide and bortezomib. Moreover, few data about the impact of prior therapies on quality of response and outcome in patients with rrMM are available. Before the introduction of novel agents, duration of response progressively shortened with subsequent regimens 44 . Similarly, patients who relapsed or became refractory to novel agents show a poor outcome in terms of both PFS and OS 45 .
As shown in Fig. 2 , in two studies, the number of previous therapy did not significantly impact on response rate in relapsed/refractory MM patients receiving either bortezomib 23 or lenalidomide monotherapy 24 . Patients included in these two studies were not matched for number of prior therapies (2 or fewer prior treatment regimens versus 3 or more in patients treated with lenalidomide; one prior line of therapy versus more than one in those receiving bortezomib). In patients heavily pre-treated, bortezomib led to a response rate similar to patients who received lenalidomide alone (at least PR 34% vs 26%). Considering the toxicities associated with lenalidomide/bortezomib and the possible presence of comorbidities, these agents could be used alone in elderly or frail heavily pretreated rrMM patients for whom preserving quality of life is essential.
A subset analysis of MM-009/MM-010 trials assessing LD, reported a higher ORR rate (67% vs 57%) and significantly longer PFS (14 months vs 9. prior therapies may impact on outcome of the 3-and 4-drug combinations described above.
However, in patients who received one prior therapy, VMPT and ThaDD-V induce CR rates similar to those obtained in newly diagnosed MM. Conversely, CR rate after PAD regimen is unexpectedly low in these patients, and is comparable to results obtained with lenalidomide plus dexamethasone (Fig. 2) . It is not clear if such results depend on the different study population, the limited number of patients enrolled, or any other reason. Of note, these more intense approaches are associated with grade 3-4 neutropenia, infection and peripheral neuropathy, hence they may be more suitable for younger patients or compliant patients at early relapse phase.
As for the type of previous therapies, mainly data on thalidomide and its impact on salvage therapy are available. Thalidomide was introduced before bortezomib and lenalidomide, and it has in fact been used more extensively. Data about previous therapy with thalidomide, summarized in Fig. 3 and Fig. 4 , are quite conflictng Patients receiving bortezomib alone 49 showed worse response and outcome if they had received prior thalidomide; on the contrary, no differences in terms of ORR and TTP were found in patients previously treated or not with thalidomide and receiving bortezomib plus pegylated liposomal doxorubicin 50 . Pooled data from MM-009/MM-010 trials showed that ORR and TTP were significantly lower in patients with prior thalidomide exposure, suggesting the possibility of a cross-resistance between thalidomide and lenalidomide. However, in this study, patients previously treated with thalidomide had a significant higher number of prior lines of therapy and a longer time from diagnosis 51 . These results are partly in contrast with those from a French retrospective analysis on patients treated with LD [47] . In this study, response rate and PFS were not affected by prior thalidomide, although progression on thalidomide negatively affected both PFS and OS. This may suggest the negative impact of thalidomide maintenance therapy [47, 52] . Nevertheless, a recent retrospective study, including a wide cohort of heavily pretreated patients, demonstrated that lenalidomide is effective in patients both thalidomideresistant or sensitive to a previous thalidomide-therapy. 53 Although only retrospective analyses are currently available, prior thalidomide seems to not affect salvage therapy with lenalidomide.
More complex regimens, such as the combinations bortezomib-dexamethasone-cyclophosphamide (BCD) 54 , bortezomib-thalidomide-dexamethasone (VTD) 55 , bortezomib-lenalidomidedexamethasone (VRD) 48 showed a significant higher efficacy in patients who did not receive prior treatment with thalidomide or who are not resistant to it (Fig 4) .
The impact of previous therapy with bortezomib is controversial. As reported in Fig. 5 , two studies [26, 47] with LD showed conflicting results: in one study previous bortezomib did not affect ORR, while in the other one ORR, PFS and OS were significantly better in patients who had not been previously treated with bortezomib. However, the two patient populations did not match for median number of previous regimens (2 vs 4, respectively). In the MM-016 study, multivariate analysis in patients treated with LD showed that prior bortezomib is an adverse risk factor affecting PFS and OS 56 . In contrast with VRD regimen 48 , ORR of patients who received PAD regimen was not affected by prior bortezomib exposure, showing the efficacy of bortezomib in consecutive lines of therapies 6 . This was also confirmed in another study using ThaDD-V combination 8 .
The recent update analysis of the VISTA trial shows that bortezomib administered as first-line treatment does not negatively affect response to lenalidomide-, thalidomide-or bortezomib-based regimens at relapse 30 . Data on the impact of previous bortezomib on subsequent salvage therapies are limited and conflicting, and they mainly derive from retrospective studies including small number of patients. Therefore, no definitive conclusion can be drawn 6,8,48 .
With regard to salvage treatment following LD, bortezomib-based regimens [57] in heavily pretreated patients led to at least PR rate 43% and prolonged. Another study on patients previously treated with lenalidomide, bortezomib in combination with lenalidomide and dexamethasone showed encouraging results (at least PR = 57%; CR = 15%) 58 . Lenalidomide, cyclophosphamide and prednisone (REP) may be another alternative option in this setting. In one trial, REP induced a response rate of 50% (CR = 14.3%) in patients refractory to LD 59 . On the contrary, thalidomidebased therapies do not exert a substantial activity in patients who received prior treatment with lenalidomide, although only results from very small study are available 60 .
A prior stem cell transplantation does not seem affect response and outcome in patients receiving new-drug combinations 48,49,61 . In patients who relapsed after single or tandem autologous stem cell transplantation (ASCT), a recent Italian study reported a significant higher response rate in patients receiving ASCT as second-line compared with those treated with thalidomide/bortezomib based-regimens (85% vs 49%; p=0.0004). However, no differences in terms of PFS or OS were detected between two groups of patients 62 .
What is the impact of cytogenetics in rrMM?
The prognostic value of chromosomal abnormalities such as del (13) (13) by FISH compared with those with normal karyotypes 66 ( Fig. 6 and Fig.   7 ). In a small Canadian study 65 , bortezomib seems to be effective in patients with t(4;14)
abnormality, while results from studies using LD combination are conflicting 47,56 . Neither bortezomib-or lenalidomide-based combination proved to overcome poor prognosis associated with 17p deletion 36,56,65 . However, no definitive conclusion can be drawn from these small retrospective trials. Moreover, other prognostic factors could be somewhat more relevant than cytogenetics in advanced disease.
An overview of new drugs of second generation
Recent early phase I and II clinical trials using new proteasome inhibitors, third-generation IMiDs and alkylating agents have produced encouraging results in terms of both efficacy and toxicity. and bortezomib-refractory patients (60%) 86 were also promising, and so was long-term response found in an extended follow-up of phase I study 88 .
The alkylating agent bendamustine is structurally similar to both alkylating agents and purine analogs, and is not cross-resistant with alkylating agents and other drugs in vitro 89 . Bendamustine showed strong activity in MM patients, also in untreated patients 90,91 . Recently, a phase I study investigated the role of bendamustine in combination with lenalidomide and dexamethasone in patients with rrMM [92] . Seven out 9 valuable patients (67%) achieved a response, including 1 VGPR and 5 PRs. The MTD of bendamustine and lenalidomide has not been identified at this point.
Grade 3/4 adverse events included neutropenia (2 patients), thrombocytopenia (1), anemia (1), hyperglycemia (1), and prolonged QT interval (1).
Several other agents targeting novel molecular mechanisms are in late-stage clinical testing (Table   3) . Unfortunately, to date none of these trials has yet reported significant single-agent activity, since some of these agents may result in a more cytostatic than cytotoxic effect. Some of these compounds have also been used in combination with bortezomib or lenalidomide in phase Ib/II trials; however, it is difficult to identify the benefit of these agents when they are used in combination with active agents 93 . Numerous other investigational agents are being considered for early-phase clinical testing. Therapeutic options for MM will continue to increase, and this will substantially improve outcomes.
Expert opinion
To date, there is no strong evidence to guide physicians in the treatment choice for rrMM, and mainly post-hoc analyses are available. Randomized studies are awaited in this context.
First-line therapy choice plays an important role. All compliant patients should receive combination therapy followed by intensification and maintenance with the aim to obtain maximal tumor burden reduction. Valid options are currently available.
The studies described in this review suggest that depth of response is a key factor also in rrMM patients. Indeed, patients attaining a deeper response, in particular CR, have a prolonged PFS.
In patients with suboptimal response to induction, type of therapy represents another crucial point.
The data presented here also suggest that in the non-transplant setting, therapy should be prolonged, Data reported in published studies showed that more intense treatment regimens including 3 of 4 drugs proved to be beneficial in rrMM. Of course, the toxicity profile of these regimens should be carefully considered. To decrease toxicity and eventually treatment discontinuation, replacing thalidomide by lenalidomide, and reducing bortezomib schedule from twice-to once-weekly administration seem to be effective actions.
As for the type of previous treatment, in patients who received prior treatment with thalidomide, Consolidation and/or maintenance therapy seems to be of benefit both in combination or sequential therapies also in rrMM. Caution is necessary when using long-term thalidomide since a prolonged exposure to thalidomide may cause peripheral neuropathy, thus limiting the choice of subsequent therapies. On the contrary, lenalidomide seems to be the best candidate for long-term treatment given its safety profile and effectiveness.
To date, there is not sufficient evidence to base therapy choice for rrMM on cytogenetics.
Second generation new-drugs, such as pomalidomide, carfilzomib, bendamustine and histonedeacetylase inhibitors, showed promising preliminary results. They will probably enter the clinical practice soon, thus expanding the treatment spectrum of multi-drug combinations, and eventually increasing the rescue possibility.
Ongoing and future studies will increase the treatment options available to rrMM patients and improve outcome . 
